ANKTIVA Approved for Commercial Use in Saudi Arabia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy IBRX?
Source: Newsfilter
- Approval Milestone: ANKTIVA (nogapendekin alfa inbakicept) has received approval from the Saudi Food and Drug Authority (SFDA) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, marking a significant strategic expansion for the company in the Middle East market.
- Patient Identification: Initial patients have been identified for ANKTIVA treatment, which not only addresses the urgent need for new cancer therapies in Saudi Arabia but also has the potential to enhance ImmunityBio's market share in the region.
- Partnership Distribution: ANKTIVA is being distributed through partnerships with Biopharma and Cigalah Healthcare, leading healthcare distribution companies in the Middle East, ensuring rapid market entry for the product.
- Growing Market Demand: The rapidly increasing cancer burden in the MENA region, particularly the rising incidence of lung and bladder cancers, underscores the urgent need for innovative treatment options, making ANKTIVA's launch timely and critical for patient care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.190
Low
5.00
Averages
7.33
High
9.00
Current: 8.190
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Potential Expansion in Japan Analyzed
- Japan Market Expansion: Traders have outlined a hypothetical scenario where ImmunityBio could secure a 10% stake from a Japanese partner through a $10 billion investment, providing capital for future supply commitments and accelerating commercialization efforts in Japan.
- Stock Price Surge: ImmunityBio's shares (IBRX) have jumped over 6% this week amid speculation regarding a potential deal in Japan, with the stock price increasing over 200% in the past year, reflecting strong market optimism about the company's global expansion plans.
- Investor Focus on Japan Approval: Retail investors are highlighting Japan's Conditional Early Approval program as a potential catalyst for faster commercialization, particularly as drugs receiving this approval become eligible for National Health Insurance reimbursement, potentially turning Japan's 125 million population into a revenue-generating clinical trial.
- Ongoing FDA Scrutiny: Despite gaining regulatory traction overseas, ImmunityBio's Anktiva remains under heavy scrutiny from the FDA, which has flagged promotional claims, contrasting with the optimistic sentiment among traders regarding the company's international expansion efforts.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Promotional Material Issues: The FDA noted that ImmunityBio's TV ads and podcast misled the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, failing to provide sufficient data to support its efficacy claims, potentially leading to broader legal and regulatory challenges.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and encouraging witnesses to assist in the investigation, demonstrating a commitment to investor rights while reflecting potential deficiencies in the company's transparency and compliance.
See More
ImmunityBio Securities Class Action Reminder
- Deadline for Lawsuit: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit, ensuring their rights are protected.
- FDA Warning Letter Revealed: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock was made public, indicating that misleading advertisements for Anktiva violated federal laws, raising concerns about public health and increasing investor apprehension regarding the company's compliance.
- Stock Price Plummets: Following the disclosure of the FDA warning letter, ImmunityBio's stock price fell by 21%, dropping $1.98 to close at $7.42, reflecting a pessimistic market sentiment about the company's future prospects and potentially eroding investor confidence further.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service, allowing investors to access relevant securities class action information through their website and connect with Kahn Swick & Foti, LLC for legal options, aiding investors in protecting their rights during legal proceedings.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions from improper promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials regarding Anktiva were misleading, particularly the claim that it could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to come forward, indicating serious concerns about the company's transparency and compliance with federal securities laws.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading claims not only undermine investor confidence but also pose a public health risk, as such false statements could lead patients to have incorrect expectations about Anktiva's effectiveness.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby alleviating the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the true information was revealed, highlighting the company's misrepresentation of its business and prospects.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for the period from April 30, 2024, to March 19, 2026, with investors claiming losses over $50,000 due to undisclosed sales to Chinese companies violating U.S. export laws, which misled investors and could severely impact the company's reputation and stock price.
- ImmunityBio Lawsuit: ImmunityBio, Inc. (NASDAQ:IBRX) is under scrutiny for the class period from January 19, 2026, to March 24, 2026, where investors allege that executives overstated Anktiva's capabilities, leading to misleading positive statements about the company's prospects, potentially affecting future funding and market trust.
- Pinterest Lawsuit: Pinterest, Inc. (NYSE:PINS) is involved in a class action for the period from February 7, 2025, to February 12, 2026, with claims that the company failed to disclose risks of declining advertising revenues and potential restructuring, which could undermine shareholder confidence and lead to stock volatility.
- Legal Consultation Opportunity: Investors are encouraged to contact The Law Offices of Frank R. Cruz before the deadlines to understand their legal rights in these class actions, highlighting the significant legal risks these companies face that may impact their future operations and financial health.
See More
ImmunityBio's Potential Expansion in Japan Analyzed
- Japan Market Expansion: Traders have outlined a hypothetical scenario where ImmunityBio could secure a 10% stake from a Japanese partner through a $10 billion investment, providing capital for future supply commitments and accelerating commercialization efforts in Japan.
- Stock Price Surge: ImmunityBio's shares (IBRX) have jumped over 6% this week amid speculation regarding a potential deal in Japan, with the stock price increasing over 200% in the past year, reflecting strong market optimism about the company's global expansion plans.
- Investor Focus on Japan Approval: Retail investors are highlighting Japan's Conditional Early Approval program as a potential catalyst for faster commercialization, particularly as drugs receiving this approval become eligible for National Health Insurance reimbursement, potentially turning Japan's 125 million population into a revenue-generating clinical trial.
- Ongoing FDA Scrutiny: Despite gaining regulatory traction overseas, ImmunityBio's Anktiva remains under heavy scrutiny from the FDA, which has flagged promotional claims, contrasting with the optimistic sentiment among traders regarding the company's international expansion efforts.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Promotional Material Issues: The FDA noted that ImmunityBio's TV ads and podcast misled the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, failing to provide sufficient data to support its efficacy claims, potentially leading to broader legal and regulatory challenges.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and encouraging witnesses to assist in the investigation, demonstrating a commitment to investor rights while reflecting potential deficiencies in the company's transparency and compliance.
See More
ImmunityBio Securities Class Action Reminder
- Deadline for Lawsuit: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit, ensuring their rights are protected.
- FDA Warning Letter Revealed: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock was made public, indicating that misleading advertisements for Anktiva violated federal laws, raising concerns about public health and increasing investor apprehension regarding the company's compliance.
- Stock Price Plummets: Following the disclosure of the FDA warning letter, ImmunityBio's stock price fell by 21%, dropping $1.98 to close at $7.42, reflecting a pessimistic market sentiment about the company's future prospects and potentially eroding investor confidence further.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service, allowing investors to access relevant securities class action information through their website and connect with Kahn Swick & Foti, LLC for legal options, aiding investors in protecting their rights during legal proceedings.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions from improper promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials regarding Anktiva were misleading, particularly the claim that it could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to come forward, indicating serious concerns about the company's transparency and compliance with federal securities laws.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading claims not only undermine investor confidence but also pose a public health risk, as such false statements could lead patients to have incorrect expectations about Anktiva's effectiveness.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby alleviating the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the true information was revealed, highlighting the company's misrepresentation of its business and prospects.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for the period from April 30, 2024, to March 19, 2026, with investors claiming losses over $50,000 due to undisclosed sales to Chinese companies violating U.S. export laws, which misled investors and could severely impact the company's reputation and stock price.
- ImmunityBio Lawsuit: ImmunityBio, Inc. (NASDAQ:IBRX) is under scrutiny for the class period from January 19, 2026, to March 24, 2026, where investors allege that executives overstated Anktiva's capabilities, leading to misleading positive statements about the company's prospects, potentially affecting future funding and market trust.
- Pinterest Lawsuit: Pinterest, Inc. (NYSE:PINS) is involved in a class action for the period from February 7, 2025, to February 12, 2026, with claims that the company failed to disclose risks of declining advertising revenues and potential restructuring, which could undermine shareholder confidence and lead to stock volatility.
- Legal Consultation Opportunity: Investors are encouraged to contact The Law Offices of Frank R. Cruz before the deadlines to understand their legal rights in these class actions, highlighting the significant legal risks these companies face that may impact their future operations and financial health.
See More
